ERT Acquires APDM Wearable Technologies to Reinvent Endpoint Measurement in Clinical Trials

ERT, the global leader in clinical endpoints data collection, today announced the acquisition of APDM Wearable Technologies (APDM, Inc.), a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient. Thereby, reinventing endpoint measurement.

Current clinical trial assessments in movement disorders such as Parkinson’s disease (PD), Multiple Sclerosis (MS), and Ataxia are subjective and based on episodic visits. Consequently, drug development decisions in Central Nervous System (CNS) and other pathologies result in large-scale trials that are costly and highly unpredictable. APDM’s wearable platform is designed to address these challenges by providing precision motion data collected with medical-grade wearable sensors and novel digital endpoints to guide critical decision-making and allow for more objective, efficient, and effective evaluation of therapies.

“We are thrilled that our advanced wearable platform will be added to ERT’s suite of proven eClinical technologies to help innovative clinical trial sponsors minimize uncertainty and risk in the development of CNS and movement disorder treatments, ultimately improving patients’ lives,” said Dr. Mateo Aboy, Co-Founder & Chairman of APDM.

As an example, by integrating high-quality Patient Reported Outcomes (PRO) data captured by ERT’s industry-leading eCOA platform with data from APDM’s wearables and digital endpoints, trial sponsors gain robust insights and more comprehensive safety and efficacy data as they develop new medical treatments for many therapies including movement-related disorders. The integrated solution can be used to support in-clinic assessments as well as in trials conducted virtually.

“To truly understand a new drug’s effect on movement disorders, sponsors need objective, real-world data that can only be captured by a medical-grade precision motion device and combined with traditional clinical endpoints for a complete view on efficacy,” said James Corrigan, President, and CEO of ERT. “APDM’s advanced technology and broad understanding of objective precision movement measurement complements ERT’s expertise in high-quality clinical trial data collection, delivering the most efficient and effective approach for trial sponsors developing new medical treatments for the millions of patients living with movement disorders today.”

Visit ert.com/wearables-and-digital-biomarkers for more information on ERT’s Wearables and Digital Biomarkers. Financial terms of the transaction were not disclosed.

Share